Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues

Print
Published on Friday, 10 June 2016

Abstract

Treatment with radiolabeled somatostatin analogs is a promising new tool in the management of patients who have inoperable or metastasized endocrine tumors.

Symptomatic improvement may occur with all (111)In-, (90)Y-, or (177)Lu-labeled somatostatin analogs that have been used for peptide receptor radionuclide therapy.

The results that were obtained with [(90)Y-DOTA degrees ,Tyr(3)]octreotide and [(177)Lu-DOTA degrees ,Tyr(3)]octreotate are encouraging in tumor regression.

Also, if kidney-protective agents are used, the side effects of this therapy are few and mild.

These data compare favorably with the limited number of alternative treatment approaches.

 

 

About this publication.

 

See also:

- Somatostatin in oncology, the overlooked evidences;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer.